FibroGen to effect 1-for-25 reverse stock split to regain Nasdaq compliance

KYNTRA BIO, INC.

Reverse split effective 5:00 p.m. ET June 16, 2025; post-split trading begins June 17.
Outstanding shares reduced from ~101.1M to ~4.0M; new CUSIP 31572Q881.
No fractional shares issued; cash paid in lieu of fractional interests.
Split approved by stockholders at June 4, 2025 annual meeting.
Aims to meet Nasdaq minimum bid price requirement (Rule 5450(a)(1)).

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

KYNTRA BIO, INC.: Effected a 1-for-25 reverse stock split of common stock via amendment to the certificate of incorporation (effective 2025-06-16).

Change: charter amendment
Effective: 2025-06-16

Exact text from the filing

On June 10, 2025, FibroGen, Inc. (“FibroGen” or the “Company”) filed a Certificate of Amendment of the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware for a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the issued and outstanding shares of the Company's Common Stock (the “Common Stock” ). The Certificate of Amendment will take effect, as of 5:00 p.m. Eastern Time on June 16, 2025 (the “Effective Time”).

View on SEC.gov

83 governance changes filed in the last 30 days. Browse all governance changes →

KYNTRA BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-25-085439

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.